U.S. market Closed. Opens in 11 hours 39 minutes

IMRX | Immuneering Corporation Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/A316.95K2.08M2.31M1.92M
Cost of Revenue764.14K158.12K1.15M1.28M1.22M
Gross Profit-764.14K158.83K926.89K1.03M696.74K
Operating Expenses57.65M51.90M34.81M18.11M6.99M
Selling, General & Admin16.25M15.61M8.27M3.11M2.71M
Research & Development41.40M36.27M26.54M15.00M4.28M
Other Operating Expenses29.27M30.05K-127.06KN/AN/A
Operating Income-58.41M-51.74M-33.89M-17.08M-6.29M
Other Expenses / Income4.94M1.23M42.84K42.66K-1.42M
Before Tax Income-53.47M-50.51M-33.84M-17.04M-7.71M
Income Tax Expenses2.00-1.23M-307.49K-84.34K351.30K
Net Income-53.47M-49.28M-33.54M-17.04M-8.06M
Interest ExpensesN/A1.01MN/AN/A351.30K
Basic Shares Outstanding28.42M26.39M26.32M25.51M25.51M
Diluted Shares Outstanding28.42M26.39M26.32M25.51M25.51M
EBITDA-57.65M-51.71M-33.89M-16.96M-7.34M
EBITDA Margin0.00%-16,316.29%-1,629.17%-733.74%-382.35%
EBIT-53.47M-49.50M-33.84M-17.12M-7.36M
EBIT Margin0.00%-15,617.23%-1,627.11%-740.82%-383.29%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙